CD274 and non-small cell lung carcinoma: Treatment has advanced and evolved over the past decade from platinum-based chemotherapy to include targeted therapies and immune checkpoint inhibitors (ICIs), including treatments targeting the programmed cell death protein-1 receptor and its ligand, programmed death ligand 1 (PD-L1), improving outcomes for patients with NSCLC, especially those without oncogenic mutations (4–6).